Bromfenac Sodium Patent Expiration
Bromfenac Sodium is Used for managing ocular inflammation, postoperative inflammation, and reducing ocular pain in patients after cataract surgery. It was first introduced by Bausch And Lomb Inc
Bromfenac Sodium Patents
Given below is the list of patents protecting Bromfenac Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prolensa | US9517220 | Bromfenac bioavailability | Nov 11, 2033 | Bausch And Lomb |
| Prolensa | US10085958 | Bromfenac bioavailability | Nov 19, 2032 | Bausch And Lomb |
| Bromsite | US8778999 | Non-steroidal anti-inflammatory ophthalmic compositions | Aug 07, 2029 | Sun Pharm |
| Bromsite | USRE50218 | Non-steroidal anti-inflammatory ophthalmic compositions | Mar 05, 2029 | Sun Pharm |
| Prolensa | US8129431 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | Sep 11, 2025 | Bausch And Lomb |
| Prolensa | US8669290 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan 16, 2024
(Expired) | Bausch And Lomb |
| Prolensa | US8754131 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan 16, 2024
(Expired) | Bausch And Lomb |
| Prolensa | US8871813 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan 16, 2024
(Expired) | Bausch And Lomb |
| Prolensa | US8927606 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan 16, 2024
(Expired) | Bausch And Lomb |
| Prolensa | US9144609 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan 16, 2024
(Expired) | Bausch And Lomb |
| Prolensa | US9561277 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan 16, 2024
(Expired) | Bausch And Lomb |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Bromfenac Sodium's patents.
Latest Legal Activities on Bromfenac Sodium's Patents
Given below is the list recent legal activities going on the following patents of Bromfenac Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9517220 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Mar, 2023 | US9144609(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2022 | US8927606 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Mar, 2022 | US10085958 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Mar, 2022 | US8871813 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Dec, 2021 | US8754131(Litigated) |
| Correspondence Address Change Critical
| 30 Aug, 2021 | US10085958 |
| Correspondence Address Change Critical
| 30 Aug, 2021 | US9517220 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Aug, 2021 | US8669290 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jun, 2020 | US9517220 |
Bromfenac Sodium's Family Patents
